-+ 0.00%
-+ 0.00%
-+ 0.00%

Piper Sandler Maintains Neutral on RxSight, Raises Price Target to $11

Benzinga·01/20/2026 13:17:44
Listen to the news
Piper Sandler analyst Adam Maeder maintains RxSight (NASDAQ:RXST) with a Neutral and raises the price target from $10 to $11.